Brightsurf Science News & Current Events

June 02, 2007
Exercise lowers insulin in breast cancer survivors
Normally sedentary breast cancer survivors who completed an exercise program reduced the levels of insulin in their blood, revealing a likely link between physical activity and better outcomes, researchers from Dana-Farber Cancer Institute in Boston reported at the annual meeting of the American Society of Clinical Oncology in Chicago.

Dasatinib shows high early response rate as first treatment for chronic myelogenous leukemia
An established second-line drug for chronic myelogenous leukemia has high response rates when given to newly diagnosed patients as their first therapy for the disease, according to early results from a phase II clinical trial at the University of Texas M.

OHSU Cancer Institute, VA researchers find way to identify which men need a second biopsy
A researcher in the Oregon Health & Science University Cancer Institute and Portland Veterans Affairs Medical Center has found a way to identify which men need a second prostate biopsy because they may be harboring life-threatening prostate cancer even though they were given a clean bill of health after their first biopsy.

VEGF Trap shows activity in patients with advanced ovarian cancer
Preliminary results of a randomized, international Phase II trial of VEGF Trap (aflibercept) show activity in patients with recurrent epithelial ovarian cancer (EOC) who had received three or four prior chemotherapy regimens and had become resistant to platinum-based chemotherapy agents.

GSK's Pazopanib shows positive results in patients with advanced renal cell carcinoma
GlaxoSmithKline today announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RCC).

Study supports activity of GEMZAR in the treatment of early-stage breast cancer
GEMZAR (gemcitabine HCl for injection), approved in combination with paclitaxel (Taxol) in the first-line, post-surgical treatment of metastatic breast cancer, was the subject of a study presented today with encouraging results in the pre-surgical treatment of breast cancer.

Flaxseed stunts the growth of prostate tumors
Flaxseed, an edible seed that is rich in omega 3-fatty acids and fiber-related compounds known as lignans, is effective in halting prostate tumor growth, according to a study led by Duke University Medical Center researchers.

Shark cartilage shows no benefit as a therapeutic agent for lung cancer
In the first scientific study of its kind, shark cartilage extract, AE-941 or Neovastat, has shown no benefit as a therapeutic agent when combined with chemotherapy and radiation for patients with advanced non-small cell lung cancer, according to researchers at the University of Texas M.

Targeted, oral agent Enzastaurin shows favorable results
Enzastaurin, an investigational targeted, oral agent under development by Eli Lilly and Company, showed encouraging results in treating patients with late-stage nonsmall cell lung cancer (NSCLC), according to data presented today at the 43rd Annual Meeting of the American Society of Clinical Oncology.

Gene variations point to why lung cancer drugs work better in Japanese vs. US patients
Recent clinical trials revealed that Japanese lung cancer patients survived longer and had a higher rate of side effects than US patients taking the same two drugs, paclitaxel and carboplatin.

Medical management of another condition may not lead to early cancer diagnosis
Being in regular contact with healthcare providers because of a chronic illness such as diabetes or heart disease doesn't necessarily mean a person is more likely to have a cancer detected early, according to a study led by Duke University Comprehensive Cancer Center researchers.

Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer
ALIMTA (pemetrexed for injection) showed additional utility in the treatment of the most diagnosed type of cancer, according to data presented today at the 43rd Annual Meeting of the American Society of Clinical Oncology.

Diet may influence survival after treatment for stage III colon cancer, study suggests
Patients with stage III colon cancer who have undergone surgery and chemotherapy with the goal of cure may have a higher risk of relapsing and dying early if they follow a predominantly

Genomic signatures identify targeted therapies for lung cancer
Any number of things can go wrong in the cells of the body to cause cancer -- and clinicians can't tell by just looking at a tumor what exactly triggered the once normal cells to turn cancerous.

Pre-operative chemotherapy does not increase survival rates for nonsmall cell lung cancer
Neo-adjuvant (pre-operative) chemotherapy does not improve survival chances of patients with resectable nonsmall cell lung cancer compared with surgery alone.

Gene therapy delivery of nerve growth factors reverses erectile dysfunction in animal model
Rats with erectile dysfunction that were injected with a gene therapy vector containing either of two nerve growth factors were able to regain normal function after four weeks, according to a study conducted by University Pittsburgh School of Medicine researchers.

MRI detects cancers missed by mammography in breast cancer patients
A unique examination of one treatment center's use of magnetic resonance imaging (MRI) in new breast cancer patients has found MRI to be superior to mammography in finding additional tumors in a breast in which cancer has already been diagnosed, and in detecting new tumors in a patient's supposedly healthy breast.

Protein may be linked to melanoma recurrence
Higher levels of a protein called S-100 in melanoma patients may correlate with a higher risk of the disease returning, say researchers at the University of Pittsburgh Cancer Institute.

Black Americans' beliefs may hamper lung cancer prevention and care
Blacks in the United States are less certain than whites about recommendations to prevent lung cancer and are more fearful of having symptoms evaluated -- beliefs that may keep them from seeking timely treatment for the disease, researchers from Dana-Farber Cancer Institute reported at the American Society of Clinical Oncology's annual meeting in Chicago.

Herb shows potential to reduce cancer-related fatigue
North Central Cancer Treatment Group researchers, based at Mayo Clinic in Rochester, Minn., have generated preliminary data suggesting that a form of American ginseng provides greater improvements in fatigue and vitality in patients who receive the highest doses tested, compared to lower doses or no treatment.

OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients
The study showed that sipuleucel-T did not significantly delay the time it took for a patient's PSA to reach a value of 3 ng/ml, the primary endpoint of the study, but it did show a prolongation in prostate-specific antigen doubling time (PSADT).

E/Tablet technology may provide benefits to patients, researchers
The old wooden clipboard and pen that patients typically encounter when providing information in a doctor's office may soon be replaced by wireless, handheld notebook-and-pen-style computers called E/Tablets.

Radium-223: An alternative treatment for prostate cancer
The bone-targeting radioisotope radium-223 has delivered promising results in a randomized trial to test its efficacy in treatment of hormone-refractory prostate cancer.

GSK's Pazopanib shows positive results in patients with advanced RCC and ovarian cancer
GlaxoSmithKline today announced results from ongoing Phase II studies of pazopanib in advanced or metastatic renal cell carcinoma (RCC) and ovarian cancer.
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.